Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
22.48 USD | +0.76% | +2.37% | +514.20% |
02/04 | North American Morning Briefing : Stocks Seen -2- | DJ |
01/04 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 69.74M 5.82B |
---|---|---|---|---|---|
Net income 2024 * | -26M -2.17B | Net income 2025 * | -46M -3.84B | EV / Sales 2024 * | - |
Net cash position 2024 * | 72.5M 6.05B | Net cash position 2025 * | 30M 2.5B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.49
x | P/E ratio 2025 * |
-13.2
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.63% |
1 day | +0.16% | ||
1 week | +2.37% | ||
Current month | +4.66% | ||
1 month | +4.07% | ||
3 months | +349.60% | ||
6 months | +462.00% | ||
Current year | +514.20% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Oakes
CEO | Chief Executive Officer | 56 | 21/22/21 |
Claudia Lopez
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Dawn Louro
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 57 | 01/17/01 | |
Tim Mayleben
BRD | Director/Board Member | 63 | 13/21/13 |
Alka Batycky
BRD | Director/Board Member | 54 | 30/23/30 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 22.48 | +0.76% | 3 659 |
26/24/26 | 22.31 | -0.80% | 14,876 |
25/24/25 | 22.49 | +1.40% | 3,928 |
24/24/24 | 22.18 | +0.13% | 9,082 |
23/24/23 | 22.15 | +0.87% | 9,225 |
Delayed Quote Nasdaq, April 29, 2024 at 11:54 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+514.20% | 69.74M | |
+1.54% | 42.75B | |
+47.70% | 41.61B | |
+11.75% | 41.34B | |
-8.83% | 26.59B | |
+6.41% | 25.49B | |
-23.28% | 18.12B | |
+29.92% | 12.24B | |
-2.58% | 11.76B | |
+8.17% | 11B |
- Stock Market
- Equities
- LABP Stock